Pacira BioSciences, Inc. PCRX Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s other commercial liabilities?
- Pacira BioSciences, Inc. (PCRX) reported other commercial liabilities of $84.96M in Q1 2026.
- How has Pacira BioSciences, Inc.'s other commercial liabilities changed year-over-year?
- Pacira BioSciences, Inc.'s other commercial liabilities increased by 6.1% year-over-year, from $80.07M to $84.96M.
- What is the long-term trend for Pacira BioSciences, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s other commercial liabilities has grown at a 6.1% compound annual growth rate (CAGR), from $70.97M to $95.6M.